文献速递膀胱癌与上尿路尿路上皮癌

FGFR3改变是否应排除肌层浸润性膀胱癌患者接受新辅助帕博利珠单抗?PURE-01研究更新结果

Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study.
PubMed 文献 · Eur Urol Oncol · 2020-05-14

PURE-01研究纳入肌层浸润性膀胱癌患者,评估FGFR3基因组改变、FGFR3活性特征及lncRNA-FGFR3亚型与病理完全缓解(CR)的关联。结果显示高FGFR3基因表达与较低CR率相关(p=0.01),但FGFR3活性或突变/融合与CR无显著相关(p=0.2和p=0.8)。结论认为FGFR3改变的肿瘤目前不应被排除在新辅助免疫治疗研究之外。

要点

  • 高FGFR3基因表达与较低CR率相关(p=0.01),但FGFR3活性或突变/融合与CR无显著相关。
  • lncRNA-FGFR3活跃亚型(N=11)具有低上皮-间质转化和免疫特征评分、高p53活性等生物学特点。
  • 目前不应将FGFR3改变的肌层浸润性膀胱癌患者排除在新辅助免疫治疗研究之外。

核心结论

  • FGFR3表达与病理缓解的关联受多因素平衡,FGFR3改变的肿瘤目前不应被排除在新辅助免疫治疗研究之外。

研究设计与样本

  • PURE-01研究更新分析,评估肌层浸润性膀胱癌患者FGFR3基因组改变(N=112)、基于转录组的FGFR3活性特征、基于lncRNA的FGFR3亚型模型及基因表达谱(后三项N=84)与病理完全缓解(CR)的关联。

主要发现

  • 17例(15.2%)存在FGFR3基因组改变,42例(50%)高FGFR3特征评分,11例(13%)为lncRNA-FGFR3活跃肿瘤。
  • 高FGFR3基因表达与较低CR率相关(p=0.01)。
  • FGFR3活性或突变/融合与CR无显著相关(p=0.2和p=0.8)。
  • lncRNA-FGFR3活跃亚型(N=11)表现为低上皮-间质转化和免疫特征评分、高p53活性、FGFR3活性和sonic hedgehog活性。

关键数值与推荐

  • 高FGFR3活性定义为特征评分高于中位值。
  • 病理完全缓解(CR)定义为ypT0N0。

临床怎么用

  • 当前不应仅凭FGFR3改变将肌层浸润性膀胱癌患者排除在新辅助免疫治疗研究之外。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the PURE-01 study, patients with muscle-invasive bladder cancer (MIBC) who achieved a pathological complete response (CR; ypT0N0) had tumor features suggesting that pre-existing immunity may promote response. We focused on fibroblast growth factor receptor-3 (FGFR3) genomic alterations (GAs) as potential tumor resistance features. The primary endpoint of our study was CR. FGFR3 GAs were assessed via comprehensive genomic profiling of sequenced DNA (N = 112), a transcriptome-based FGFR3 activity signature, an FGFR3 subtyping model based on long noncoding RNA (lncRNA), and gene expression profiling (N = 84 for all three). We used Wilcoxon rank-sum tests, Fisher's exact test, and logistic regression analyses to analyze the associations between the various FGFR3 alterations and CR. High FGFR3 activity was defined as a signature score that was higher than the median value. Cases that were positive for lncRNA-FGFR3 subtype (lncRNA-FGFR3 active, N = 11) had consistent biology with published data: low epithelial-mesenchymal transition and immune-signature scores, high p53 activity, FGFR3 activity, and sonic hedgehog activity. In total, 17 (15.2%), 42 (50%), and 11 patients (13%) showed FGFR3 GAs or high FGFR3 signature scores, or had lncRNA-FGFR3-active tumors. Despite an association of high FGFR3 gene expression with a lower CR rate (p = 0.01), we did not find a correlation between FGFR3 activity or mutation/fusion and CR (p = 0.2 and p = 0.8). We conclude that the association of FGFR3 expression with pathological response is balanced by multiple factors. Overall, FGFR3-altered tumors should not be excluded from neoadjuvant immunotherapy studies at this time. PATIENT SUMMARY: In patients with muscle-invasive bladder cancer treated within the PURE-01 trial, we analyzed the role of fibroblast growth factor receptor-3 (FGFR3) alterations, at the DNA and RNA levels, in association with the pathological response. We did not find any robust association, mainly when analyzing the landscape of alterations defining tumors with higher biological FGFR activity. Overall, FGFR3 activity and gene alterations did not provide sufficiently robust data to exclude patients whose tumors harbor these alterations from neoadjuvant immunotherapy trials.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Necchi A, Raggi D, Giannatempo P, et al. Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study. Eur Urol Oncol. 2020. PMID: 32417369. doi:10.1016/j.euo.2020.04.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。